Sarcopenia
Conditions
Keywords
Sarcopenia, Muscular atrophy, Frailty, Acute illness, Ageing, Protein supplementation, Whey protein, Resistance training, Strength training
Brief summary
The purpose of the study is to investigate if an increased protein intake, in the form of a protein-enriched, milk-based supplement, can enhance the beneficial effect of resistance training, offered during hospitalization and 12 weeks post discharge, in older patients. This will in part be evaluated from measures of muscle strength, muscle mass and physical functioning. Also, the study population's acceptance of the intervention product will be assessed along with measures related to 'cost-effectiveness'. A sub-study will be performed in a sub-group (n=30) to investigate if bio-impedance analysis (BIA) correlates with Dual-Energy X-ray absorptiometry (DXA) at single time points, and to see if it is possible to track changes in lean body mass. In addition, the reliability of the bio-impedance analyzer will be evaluated. Also, the prevalence and classification of sarcopenia will be assessed at baseline, and correlations to nutritional status will be investigated (n=120).
Detailed description
Main study: The study design is a block randomised, double-blind, placebo-controlled, multicentre intervention study. A total of 120 hospitalized older adults, above 70 years, will be recruited consecutively from the medical departments of three Hospitals in the Capital Region of Denmark (n=40 each place). Participants will be randomized into two groups - one group receives protein-enriched, milk-based supplements and the other group receives iso-energetic placebo products. Both groups participate in the same standardized resistance training program, and will be blinded to the supplement content. One training session consists of three exercises of the lower extremities (3 sets of 10 repetitions, pursuing an intensity of 8-12 repetition maximum (RM)). While admitted, supervised resistance training is offered daily. After discharge, the participants are encouraged to perform the same program as self-training four times per week.To ensure progression (or regression if necessary) the participants receive follow-up home visits by a physiotherapist, and thus after discharge the participants are closely monitored. All participants, irrespective of allocation, will get a daily vitamin D supplement. The study duration for each participant starts while admitted to hospital and lasts until 12 weeks after discharge. Endpoint assessments will be performed at baseline (\> 72-h after admission to hospital), after discharge (\> 72-h) and 12 weeks (± 2 days) after discharge. A few endpoints will be collected during follow-up (6 months post intervention). Data will be collected by study investigators blinded to the allocation of the participants. Sub-study: 'Validation of a portable bio-impedance analyzer in a population of older adults ≥ 70 years for the assessment of muscle mass and changes in muscle mass over time' A sub-study will be performed to investigate if the portable InBody-230 BIA correlate with DXA at single time points in 30 hospitalized older people ≥ 70 years, and to see if it is possible to track changes in LBM during the 12-week intervention. Total LBM, total fat mass, and percent LBM will be measured and compared as well as appendicular and trunk LBM. In addition, the reliability of the portable bio-impedance analyzer will be evaluated by assessing the degree of agreement between two subsequent measurements. In continuation of recruitment to the primary study, a subset of participants (n=30) will be asked if they want to participate in this sub-study, irrespective of their allocation in the main study. The measurements are going to be performed twice, while hospitalized and 12 weeks after discharge (± 5 days). Sub-study: 'Prevalence of sarcopenia and investigation of the relationship between nutritional status and the EWGSOP conceptual stages for sarcopenia in hospitalized older patients \> 70 years'. The prevalence and classification of sarcopenia among Danish hospitalized older patients ≥ 70 years old (n=120) will be evaluated, according to the EWGSOP definition (Hand-grip-strength, 4-m gait speed, Bio-Impedance analysis). Also, examination of the relationship between measurements of nutritional status and the EWGSOP stages for sarcopenia (i.e. no sarcopenia, pre-sarcopenia, sarcopenia and severe sarcopenia) will be assessed at baseline. Nutritional status will be assessed according to BMI (\< 18.5, 18.5-20.5, 20.5-25, \> 25), Mini Nutritional Assessment (MNA) (no MN, risk of MN, MN), Malnutrition Universal Screening Tool (MUST) (low risk of MN, medium risk of MN, high risk of MN), and NRS-2002 (no MN, mild MN, moderate MN, severe MN) Results will be communicated to the general population and published in peer-reviewed journals.
Interventions
Daily intake of supplement
Daily intake of supplement
Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
Sponsors
Study design
Eligibility
Inclusion criteria
* Men and women aged ≥ 70 years old * Able to speak and understand Danish * Expected length of stay \> 3 days (evaluated by medical staff at department) * Ability to stand independently without walking aids * Admitted to the medical departments of Gentofte or Herlev Hospital or Rigshospitalet-Glostrup
Exclusion criteria
* Active cancer * Renal insufficiency (eGFR \< 30 mL/min/1.73m2) * Cognitive impairment (not able to comprehend the purpose of the study/give informed consent) * Terminal disease * Exclusively receiving enteral or parenteral nutrition * Milk/lactose allergy or intolerance * Planning to lose weight/go on a special diet * Planned transfer to other hospitals/departments * Pacemaker/other implanted electrical stimulants (due to Bio-Impedance Analysis (BIA) measurements) * Not being able to lie still in seven minutes (only an
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in 30-s chair stand performance | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Number of stand-ups from a chair in 30 seconds (modified version, help from armrests are allowed). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trunk lean body mass | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Trunk lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System). |
| Change in Activities of daily living (ADL) | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Use of Barthel-100 |
| Change in cognitive functioning | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Use of Mini Mental State Examination (MMSE) |
| Use of home care | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Interview: (yes/no) |
| Residence | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Interview: (own home, nursing home/assisted living facility, 24-hour rehabilitation facility) |
| Use of gait aid | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Interview: yes/no/cannot walk and registration of specific gait help |
| Length of hospital stay (LOS) | Day of discharge (from hospital) | The in-hospital intervention period (date of recruitment until date of discharge) (days) |
| Readmission to hospital | From discharge until 12 weeks post discharge, and 6 months post discharge | Frequency (number) |
| Length of total hospital stay for readmissions | From discharge until 12 weeks post discharge, and 6 months post discharge | Total length (days). |
| Mortality | From discharge until 12 weeks post discharge, and 6 months post discharge | Mortality (yes/no) |
| Change in health related Quality of life | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Questionnaire: Euroqol EQ-5D-3L |
| Change in Body weight | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Measured to the nearest 0.1 kg using a calibrated scale |
| Study population acceptance of product | 12 weeks post discharge | Self-administered evaluation-questionnaire |
| Change in mobility | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Use of De Morton Mobility Index (DEMMI) |
| Total lean body mass | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System). |
| Appendicular lean body mass | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Appendicular lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System). |
| Change in hand grip strength | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | Isometric hand grip strength (kg) (Saehan Medical digital dynamometer, 2012). |
| Change in 4 m gait speed | Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge | The time used for walking 4 m (m/s and s ) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Reliability of bio-impedance analyzer in sub-group (n=30) | Baseline (while admitted to hospital) | Degree of agreement between two subsequent measurements. |
| Prevalence of sarcopenia | Baseline (while admitted to hospital) | According to the EWGSOP definition (yes/no). |
| Classification of sarcopenia | Baseline (while admitted to hospital) | According to the EWGSOP definition (pre-sarcopenia, sarcopenia, and severe sarcopenia). |
| Nutritional status - Body mass index (BMI) | Baseline (while admitted to hospital) | According to BMI (kg/m2) (\< 18.5, 18.5-20.5, 20.5-25, \> 25) |
| Nutritional status - Mini Nutritional Assessment (MNA) | Baseline (while admitted to hospital) | According to Mini Nutritional Assessment (MNA) (no malnutrition, risk of malnutrition, malnutrition). |
| Nutritional status - Malnutrition Universal Screening Tool (MUST) | Baseline (while admitted to hospital) | According to Malnutrition Universal Screening Tool (MUST) (low risk of MN, medium risk of MN, high risk of MN) |
| Nutritional status - Nutritional Risk Screening 2002 (NRS-2002) | Baseline (while admitted to hospital) | According to Nutritional Risk Screening 2002 (NRS-2002) (no MN, mild MN, moderate MN, severe MN). |
| Energy intake | 4 days while admitted to hospital, or shorter if discharged | Daily registration schemes with pre-printed hospital foods and drinks (energy, kJ/kg). |
| Protein intake | 4 days while admitted to hospital, or shorter if discharged | Daily registration schemes with pre-printed hospital foods and drinks (protein, g/kg). |
| Level of daily activity | From discharge until 12 weeks post discharge | Activity interviews x 4 (recall interviews for the previous week) |
| Fat mass (sub group n=30) | Baseline (while admitted to hospital) and 12 weeks post discharge | Total mass. Evaluated by whole-body dual energy x-ray absorptiometry (DXA)-scanning and bio-impedance analysis (BIA). |
| Lean body mass (sub group n=30) | Baseline (while admitted to hospital) and 12 weeks post discharge | Lean body mass (total, appendicular, and trunk) evaluated by whole-body dual energy x-ray absorptiometry (DXA)-scanning. |
Countries
Denmark